TransMedics Group, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for TransMedics Group, Inc. (TMDX), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TMDX insiders buying or selling?
In the last 12 months, TransMedics Group, Inc. insiders reported 2 open-market purchases ($1.1M) and 10 sales ($4.9M) — net selling of $3.8M. Since May 2019, Trabud has recorded 197 Form 4 filings for TMDX: 7 buys ($4.4M) and 190 sells ($176.3M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $1.0M by Waleed H Hassanein (President & CEO) on Nov 18, 2025. SEC ↗
- The most recent open-market purchase was reported on Sep 14, 2026 (34 days ago).
Key Statistics (May 2019 – Sep 14, 2026)
Total Form 4 filings
197
SEC EDGAR
Insider filers
18
Insider buys (7)
$4.4M
Insider sells (190)
$176.3M
Insider sentiment
Net sellingNet insider flow of $172.0M in net selling since May 2019, and $3.8M in net selling over the last 12 months. 1 insider buy in the last 90 days.
Recent TMDX insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | David Weill | Director | Purchase | 1.3K | $81.63 | $109.1K | SEC ↗ |
| Jun 17, 2026 | Thomas J. Gunderson | Director | Sale | 9.6K | $75.06 | $722.4K | SEC ↗ |
| Mar 6, 2026 | Stephanie Lovell | Director | Sale | 1.2K | $149.62 | $178.5K | SEC ↗ |
| Mar 6, 2026 | David Weill | Director | Sale | 3.6K | $146.82 | $524.3K | SEC ↗ |
| Mar 5, 2026 | Gerardo Hernandez | Chief Financial Officer | Sale | 7.6K | $146.81 | $1.1M | SEC ↗ |
| Mar 5, 2026 | Anil P. Ranganath | Senior Vice President, General Counsel and Secretary | Sale | 864 | $139.12 | $120.2K | SEC ↗ |
| Mar 5, 2026 | Nicholas Corcoran | SVP of Supply Chain and Operations | Sale | 3.0K | $139.12 | $412.6K | SEC ↗ |
| Dec 5, 2025 | David Weill | Director | Sale | 5.0K | $138.64 | $693.2K | SEC ↗ |
| Dec 5, 2025 | Gerardo Hernandez | Chief Financial Officer | Sale | 920 | $139.62 | $128.5K | SEC ↗ |
| Nov 26, 2025 | Anil P. Ranganath | Senior Vice President, General Counsel and Secretary | Sale | 3.0K | $145.22 | $435.7K | SEC ↗ |
| Nov 18, 2025 | Waleed H Hassanein | President & CEO | Purchase | 8.8K | $114.00 | $1.0M | SEC ↗ |
| Oct 31, 2025 | Edward M Basile | Director | Sale | 4.1K | $130.45 | $540.3K | SEC ↗ |
| Aug 5, 2025 | Edward M Basile | Director | Sale | 4.1K | $125.51 | $520.0K | SEC ↗ |
| Jun 10, 2025 | Anil P. Ranganath | Senior Vice President, General Counsel and Secretary | Sale | 686 | $139.80 | $95.9K | SEC ↗ |
| May 29, 2025 | Edward M Basile | Director | Sale | 5.0K | $126.45 | $632.3K | SEC ↗ |
| May 23, 2025 | David Weill | Director | Sale | 732 | $123.88 | $90.7K | SEC ↗ |
| May 13, 2025 | Edward M Basile | Director | Sale | 6.0K | $115.63 | $693.8K | SEC ↗ |
| Mar 5, 2025 | Tamer I Khayal | Chief Commercial Officer | Sale | 2.4K | $76.43 | $184.0K | SEC ↗ |
| Jan 10, 2025 | Tamer I Khayal | Chief Commercial Officer | Sale | 1.1K | $80.05 | $86.7K | SEC ↗ |
| Dec 4, 2024 | Tamer I Khayal | Chief Commercial Officer | Sale | 1.1K | $86.40 | $93.7K | SEC ↗ |
| Nov 13, 2024 | Tamer I Khayal | Chief Commercial Officer | Sale | 1.5K | $90.04 | $131.3K | SEC ↗ |
| Nov 7, 2024 | Edward M Basile | Director | Sale | 6.8K | $83.55 | $564.0K | SEC ↗ |
| Nov 5, 2024 | Tamer I Khayal | Chief Commercial Officer | Sale | 1.1K | $82.64 | $89.5K | SEC ↗ |
| Oct 17, 2024 | Waleed H Hassanein | President & CEO | Sale | 8.6K | $132.71 | $1.1M | SEC ↗ |
| Oct 3, 2024 | Tamer I Khayal | Chief Commercial Officer | Sale | 3.0K | $148.24 | $438.5K | SEC ↗ |
Showing the 25 most recent of 197 Form 4 filings for TransMedics Group, Inc..
Most active TMDX insiders
- Tamer I Khayal42 filings
- Waleed H Hassanein35 filings
- John F Carey33 filings
- Stephen Gordon28 filings
- Edward M Basile12 filings
Ask anything about TMDX insider activity
Use Trabud's AI agent to query TransMedics Group, Inc.'s Form 4 history in plain English — "Show me TMDX CEO purchases this year" or compare it against any other ticker.
Open the AI agentTMDX insider trading FAQ
Are TransMedics Group, Inc. insiders buying or selling?
In the last 12 months, TransMedics Group, Inc. insiders reported 2 open-market purchases ($1.1M) and 10 sales ($4.9M) — net selling of $3.8M. Since May 2019, Trabud has recorded 197 Form 4 filings for TMDX: 7 buys ($4.4M) and 190 sells ($176.3M). Over the full record that is net selling of $172.0M.
How many insiders trade TMDX stock?
18 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for TransMedics Group, Inc.. The most recent filing was accepted on Sep 14, 2026.
Where does Trabud get TMDX insider trading data?
All TMDX insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.